ABBVIE

Continuity Biosciences, LLC launches with a focus on cell reprogramming, immune modulation, and drug delivery technologies, aiming to enhance therapies for chronic diseases. Founded by industry veterans, the company leverages licensed platforms from Houston Methodist Hospital for implantable nanofluidic systems, supported by significant funding.

DelveInsight's 'Spinal Cord Injury Pipeline Insight, 2024' report details 35+ therapies in development by 35+ companies, including Athersys, Olatec Therapeutics, and AbbVie, focusing on mechanism of action, clinical trials, and market prospects. Key therapies include Allogeneic stem cell therapy, OLT1177, and Elezanumab, with ongoing trials and potential market impact. The report covers pre-clinical to marketed phases, regulatory approvals, and market dynamics.

AbbVie Inc's emraclidine failed two Phase 2 trials for schizophrenia, impacting Bristol Myers Squibb's Cobenfy competition. Despite this, analysts remain positive on AbbVie's immunology franchise, though BMO Capital Markets lowered their price target to $208.

The Personalized Medicine Coalition (PMC) appoints Amy Nicole Nayar, Pharm.D., M.S., as its next President and CEO, effective January 1, 2025. Dr. Nayar, a leader in patient-centered change, will advance PMC's mission in education, advocacy, and evidence development for personalized medicine.

Bristol Myers Squibb stock rose 10% after AbbVie's mid-stage clinical trials for Emraclidine failed, boosting BMY's recently FDA-approved schizophrenia drug Cobenfy. BMY's revenue rose 1% to $47 billion, with new drugs like Camzyos, Sotyktu, and Opdualag expected to generate over $1 billion each by 2026. Despite a slight decline in operating margin to 15.3%, BMY's recent acquisitions and Cobenfy's potential peak sales of over $6 billion suggest growth potential.

AbbVie's failed Phase 2 trial for schizophrenia drug emraclidine benefits Bristol Myers Squibb's Cobenfy, which was approved by the FDA in September.

AbbVie's $9B neuroscience bet falters, AstraZeneca resubmits lung cancer drug, 23andMe halts drug development, ALS startup Trace Neurosciences raises $101M, Neurogene's gene therapy faces severe side effect, Pfizer explores wearables in drug trials.

AbbVie's stock dropped 12% after emraclidine, a schizophrenia treatment, failed Phase II trials. In contrast, Bristol Myers Squibb's KarXT showed positive Phase III results, leading to a 11% stock rise.